Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Duloxetine Update

Duloxetine (Cymbalta®) is an antidepressant that has been the subject of several previous postings. Some of this information is now in need of an update.

To clarify the current situation:

  • The Scottish Medicines Consortium have restricted use of duloxetine in Scotland
  • Lancashire Care Trust have restrictions in place on duloxetine
  • The Summary of Product Characteristics recommends that patients (and carers) are made aware of the need to monitor for suicidal ideation/behaviour and that there is "close supervision of high-risk patients"
  • The MHRA publication Current Problems in Pharmacovigilance recommends "careful and frequent patient monitoring during treatment is recommended, particularly for high risk groups."
  • [Update] Leeds NHS Health Community (PCT, Acute and Care Trusts) have recommended restricted use of duloxetine

Action: The existing advice remains unchanged at this time; duloxetine should not be used as an antidepressant in a Primary Care Setting.

Share 'Duloxetine Update' on Email Share 'Duloxetine Update' on Delicious Share 'Duloxetine Update' on Digg Share 'Duloxetine Update' on Facebook Share 'Duloxetine Update' on Google+ Share 'Duloxetine Update' on reddit Share 'Duloxetine Update' on StumbleUpon Share 'Duloxetine Update' on Twitter

atomic-wealth

No Comments to “Duloxetine Update”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,668 spam comments.

atomic-wealth
fond-illness
summer